Drug
Abo 102
Abo 102: highest development phase Phase 1/2, developed by Ultragenyx Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| ABO-102 NCT04088734 | Phase 1/2 | MPS IIIA |
Latest
No recent events.
Follow Abo 102 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.